Search

Author/Creator Jiang, Yusang

1. Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis. Issue 4 (17th March 2021)

Authors:
McInnes, Iain B.; Rahman, Proton; Gottlieb, Alice B.; Hsia, Elizabeth C.; Kollmeier, Alexa P.; Chakravarty, Soumya D.; Xu, Xie L.; Subramanian, Ramanand A.; Agarwal, Prasheen; Sheng, Shihong; Jiang, Yusang; Zhou, Bei; Zhuang, Yanli; van der Heijde, Désirée; Mease, Philip J.
Journal:
Arthritis & rheumatology
Issue:
Volume 73:Issue 4(2021)
Page Start:
604
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Issue 5 (26th February 2018)

Authors:
Taylor, Peter C; Schiff, Michael H; Wang, Qingmin; Jiang, Yusang; Zhuang, Yanli; Kurrasch, Regina; Daga, Shruti; Rao, Ravi; Tak, Paul P; Hsu, Benjamin
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77:Issue 5(2018)
Page Start:
658
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced. Issue 1 (10th February 2021)

Authors:
Ritchlin, Christopher T; Helliwell, Philip S; Boehncke, Wolf-Henning; Soriano, Enrique R; Hsia, Elizabeth C; Kollmeier, Alexa P; Chakravarty, Soumya D; Zazzetti, Federico; Subramanian, Ramanand A; Xu, Xie L; Zuraw, Qing C; Sheng, Shihong; Jiang, Yusang; Agarwal, Prasheen; Zhou, Bei; Zhuang, Yanli...
Journal:
RMD open
Issue:
Volume 7:Issue 1(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis. Issue 3 (7th February 2022)

Authors:
McInnes, Iain B.; Rahman, Proton; Gottlieb, Alice B.; Hsia, Elizabeth C.; Kollmeier, Alexa P.; Xu, Xie L.; Jiang, Yusang; Sheng, Shihong; Shawi, May; Chakravarty, Soumya D.; van der Heijde, Désirée; Mease, Philip J.
Journal:
Arthritis & rheumatology
Issue:
Volume 74:Issue 3(2022)
Page Start:
475
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis. Issue 1 (24th February 2023)

Authors:
Gottlieb, Alice B; McInnes, Iain B; Rahman, Proton; Kollmeier, Alexa P; Xu, Xie L; Jiang, Yusang; Sheng, Shihong; Shawi, May; Chakravarty, Soumya D; Lavie, Frederic; Mease, Philip J
Journal:
RMD open
Issue:
Volume 9:Issue 1(2023)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study. Issue 3 (10th February 2023)

Authors:
Ritchlin, Christopher T.; Deodhar, Atul; Boehncke, Wolf‐Henning; Soriano, Enrique R.; Kollmeier, Alexa P.; Xu, Xie L.; Zazzetti, Federico; Shawi, May; Jiang, Yusang; Sheng, Shihong; Helliwell, Philip S.
Journal:
ACR open rheumatology
Issue:
Volume 5:Issue 3(2023)
Page Start:
149
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies. Issue 1 (16th March 2022)

Authors:
Ritchlin, Christopher T; Mease, Philip J; Boehncke, Wolf-Henning; Tesser, John; Schiopu, Elena; Chakravarty, Soumya D; Kollmeier, Alexa P; Xu, Xie L; Shawi, May; Jiang, Yusang; Sheng, Shihong; Wang, Yanli; Xu, Stephen; Merola, Joseph F; McInnes, Iain B; Deodhar, Atul
Journal:
RMD open
Issue:
Volume 8:Issue 1(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗